Actigen

Actigen Limited is a biotechnology company specializing in the development of innovative therapies for rare diseases. The company's primary focus is on mucopolysaccharidosis II (MPS II, also known as Hunter syndrome). Actigen Limited is located in Cambridge, UK, with its address at St John’s Innovation Centre, Cowley Road, CB4 0WS. The company operates within the healthcare, biotechnology, and pharmaceutical industries. Actigen Limited collaborates with pharmaceutical partners to develop its therapies. The company employs inventive trial designs to improve patient outcomes and quality of life. Actigen Limited has a long-standing partnership with Generium for developing GNR-055. The company's team includes Michael Braunagel, the Managing Director; Stig Jarle Pettersen, Financial Advisor and Board Member; Alex Duncan, Board Member; Kamilla Rolsted, Business Development; Ro Gardner, Operations Communications; Peter Bach, Programme Lead; Julie Foulkes, Regulatory Affairs Advisor; Allison Morgan, Clinical Research Advisor; John Powell, Pharmaceutical Physician; and Peter Treasure, Statistician. Actigen Limited's competitive advantages include an experienced team with a common goal of improving patient outcomes, a collaborative approach with trusted pharmaceutical partners, and inventive trial designs tailored to patient needs. The company is patient-focused, collaborative, and staffed by experts. Actigen Limited can be contacted via phone at +44 (0) 01223 422062 or via email at [email protected] or [email protected].